All Vaccinology articles
-
NewsResearchers find a common weakness in major gut pathogens
The bacteria enterotoxigenic E. coli and Shigella together cause hundreds of millions of infections each year and are among the leading causes of diarrheal death, especially in children. A shared biological feature of these gut pathogens could lead to a vaccine that protects against both.
-
NewsA new HIV vaccine study reveals new hope—and new challenges—for aging patients
A new clinical trial demonstrates that novel vaccines can significantly boost T cells targeting and could contribute to curative approaches against HIV.
-
NewsResearcher secures nearly $4 million NIH grant to advance therapeutic vaccine to help end genital herpes
University of California, Irvine immunologist Lbachir BenMohamed has been awarded a $3.93 million National Institutes of Health grant to develop and test a novel therapeutic vaccine designed to prevent recurrent genital herpes.
-
NewsShingles vaccine linked to lower dementia risk in older adults, study suggests
A target trial emulation of older adults entering skilled-nursing facilities found that those who received the recombinant shingles vaccine (RZV) had a lower risk of developing dementia over the following four years compared with those who were not vaccinated.
-
NewsmRNA flu vaccine offers immune protection against wide array of influenza virus strains
A new study has found that an investigational mRNA influenza vaccine helps the immune system recognize a wider range of influenza viruses than today’s standard flu shot, offering stronger and potentially longer-lasting protection. The vaccine, developed by Moderna, is currently under review by the U.S. Food and Drug Administration.
-
NewsScientists track breakthrough single-dose vaccines for Andes hantavirus strain
Researchers report the development of new vaccines that, in animal testing, provided full protection against the deadly Andes hantavirus after a single dose. They are working to fast-track these single-dose vaccines into human clinical trials.
-
NewsThousands of young people to be offered two-dose MenB vaccine ahead of autumn
Thousands of young people across England will get protection against meningococcal B disease (MenB) through a one-off vaccination programme launching ahead of the 2026 academic year.
-
NewsFirst-in-human clinical trial shows promising results for new Lassa fever vaccine
Researchers have reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.
-
NewsTesting AI against public health’s existing tools
A new study found that AI chatbots made vaccine-hesitant parents more likely to say they would vaccinate their children against HPV, but did not outperform materials from government health agencies, whose effects also lasted longer.
-
NewsAccelerating chikungunya vaccine development in Africa: Launch of the ACT-CHIK Project
Funded by the Global Health EDCTP3 Joint Undertaking, a new €15.3 million project coordinated by Institut Pasteur brings together seven partners across four continents to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa.
-
NewsResearchers develop new vaccine adjuvant that could make it easier to eradicate polio
Researchers have now come up with a way to modify the injectable polio vaccine so that it can also promote a mucosal immune response. This vaccine could help to achieve polio eradication while avoiding the risks of the oral polio vaccine.
-
NewsStudy reveals core values that drive Black and Hispanic parents’ decisions on vaccinating their kids against COVID-19
Persistently low rates of COVID-19 vaccination in Black and Hispanic children suggest that parents in these communities tend to be hesitant about the vaccine for their kids, even when they have received it themselves. A new study sheds light on the factors influencing decisions about vaccination.
-
NewsDengue vaccine shows favorable safety profile in travellers from non-endemic regions
A prospective study of more than 1,000 people vaccinated with TAK-003 in Catalonia found no serious adverse events and provides new evidence on the vaccine’s short-term safety in travelers.
-
News CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates
The Coalition for Epidemic Preparedness Innovations (CEPI) will urgently accelerate development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda.
-
NewsPhase 1 clinical trial set to begin on first leishmaniasis vaccine
A phase 1 clinical trial testing the safety of a leishmaniasis vaccine is set to begin in the coming months. The live vaccine, found to be safe in animals, is expected to be tested in humans later this year.
-
NewsNew analysis confirms benefits of childhood flu vaccines
Pediatric flu vaccines significantly reduce the number of childhood cases of influenza, new research confirms. The findings show that for every 100 children vaccinated, between nine and 14 fewer children catch the flu.
-
NewsHealth researchers call for support to develop pandemic prevention
The Vanderbilt Center for Antibody Therapeutics has received large-scale government grants and contracts to fund the discovery of human antiviral antibodies. The problem is the next step — finding corporate partners to develop the antibodies through human testing.
-
NewsExperts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus
In response to the current outbreak of Ebola disease caused by Bundibugyo virus, WHO convened several of its expert and advisory groups to assess potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD).
-
NewsExperimental HIV vaccine achieves a long-sought goal
In a first for the field, all non-human primates given a new series of vaccines generated antibodies capable of fighting multiple strains of HIV. It brings researchers closer to a vaccine effective against the vast diversity of HIV strains circulating worldwide.
-
NewsScientists fight antimicrobial resistance by treating diseases with human antibodies
In a review, researchers highlight the promise of using human monoclonal antibodies (mAbs) to treat patients more effectively and tackle AMR. They say AMR needs to be addressed with multiple and differentiated strategies, and vaccines and mAbs are the most promising tools.